NIKKEI 225
26,577.35 +149.70 (+0.57%) HANG SENG
19,836.51 -62.26 (-0.31%) CRUDE OIL
108.37 -2.12 (-1.92%) GOLD FUTURES
1,806.30 -1.90 (-0.11%) DOW
32,196.66 +466.36 (+1.47%) BTC-GBP
24,832.06 +565.77 (+2.33%)
4D pharma plc (DDDD.L)
- Business Wire
4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022
LEEDS, England, March 31, 2022--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today reported financial results for the full year ending December 31, 2021 and highlighted its key corporate objectives for 2022.
- Business Wire
4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma
LEEDS, England, March 23, 2022--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that in Part B of its signal finding study of MRx0518 in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with solid tumors that have progressed on a prior immune checkpoint inhibitor (ICI), the renal cell carcinoma (RCC) group has met its
